
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : NG101
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Ora, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
Details : NG101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Macular Degeneration.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 09, 2023
Lead Product(s) : NG101
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Ora, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
